Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.19.8279

Associations Between TLR9 Polymorphisms and Cancer Risk: Evidence from an Updated Meta-analysis of 25,685 Subjects  

Wan, Guo-Xing (Department of Pathology and the Key Laboratories for Xinjiang Endemic and Ethnic Diseases (a joint venture with the Chinese Ministry of Education), Shihezi University School of Medicine)
Cao, Yu-Wen (Department of Pathology and the Key Laboratories for Xinjiang Endemic and Ethnic Diseases (a joint venture with the Chinese Ministry of Education), Shihezi University School of Medicine)
Li, Wen-Qin (Department of Pathology and the Key Laboratories for Xinjiang Endemic and Ethnic Diseases (a joint venture with the Chinese Ministry of Education), Shihezi University School of Medicine)
Li, Yu-Cong (Department of Pathology and the Key Laboratories for Xinjiang Endemic and Ethnic Diseases (a joint venture with the Chinese Ministry of Education), Shihezi University School of Medicine)
Zhang, Wen-Jie (Department of Pathology and the Key Laboratories for Xinjiang Endemic and Ethnic Diseases (a joint venture with the Chinese Ministry of Education), Shihezi University School of Medicine)
Li, Feng (Department of Pathology and the Key Laboratories for Xinjiang Endemic and Ethnic Diseases (a joint venture with the Chinese Ministry of Education), Shihezi University School of Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.19, 2014 , pp. 8279-8285 More about this Journal
Abstract
A meta-analysis incorporating 34 case-control studies from 19 articles involving 12,197 cases and 13,488 controls was conducted to assess the effects of three genetic variants of Toll-like receptor 9 (TLR9): rs187084, rs352140, and rs5743836. Studies on associations between TLR9 polymorphisms and cancer risk were systematically searched in electronic databases. The reported odds ratios (OR) and 95% confidence intervals (CI) were pooled to assess the strength of any associations. The results showed that the rs187084 polymorphism was significantly associated with an increased risk of cancer (CC vs TC+TT: OR=1.14, 95% CI=1.02-1.28), specifically cervical cancer (C vs T: OR=1.19, 95% CI=1.05-1.34; TC vs TT: OR=1.32, 95% CI=1.10-1.58; CC vs TT: OR=1.31, 95% CI=1.03-1.68; CC+TC vs TT: OR=1.32, 95% CI=1.11-1.56), and that this association was significantly positive in Caucasians (CC vs. TC+TT: OR=1.18, 95% CI=1.01-1.38). The rs352140 polymorphism had a protective effect on breast cancer (GA vs GG: OR=0.77, 95% CI=0.66-0.89), whereas the rs5743836 polymorphism was likely protective for digestive system cancers (CC+TC vs TT: OR=0.81, 95% CI=0.66-0.98). In conclusion, our results suggest that the rs187084 polymorphism may be associated with an elevated cancer risk, whereas polymorphisms of rs352140 and rs5743836 may play protective roles in the development of breast and digestive system cancers, respectively. From the results of this meta-analysis further large-scale case-control studies are warranted to verify associations between TLR9 polymorphisms and cancer.
Keywords
Toll-like receptor 9; polymorphisms; cancer risk; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Aderem A, Ulevitch RJ (2000). Toll-like receptors in the induction of the innate immune response. Nature, 406, 782-7.   DOI   ScienceOn
2 Castro FA, Forsti A, Buch S, et al (2011). TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer, 47, 1203-10.   DOI
3 Ashton KA, Proietto A, Otton G, et al (2010). Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. BMC Cancer, 10, 382.   DOI   ScienceOn
4 Bondar T, Medzhitov R (2013). The origins of tumor-promoting inflammation. Cancer Cell, 24, 143-4.   DOI
5 Carvalho A, Cunha C, Almeida AJ, et al (2012). The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma.Genes Immun, 13, 197-201.   DOI
6 Chen X, Wang S, Liu L, et al (2012). A genetic variant in the promoter region of Toll-like receptor 9 and cervical cancer susceptibility. DNA Cell Biol, 31, 766-71.   DOI
7 Chuang TH, Ulevitch RJ (2000). Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw, 11, 372-784.
8 Cochran WG (1950). The comparison of percentages in matched samples. Biometrika, 37, 256-66.   DOI
9 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI   ScienceOn
10 Etokebe GE, Knezevic J, Petricevic B, et al (2009). Singlenucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer. Genet Test Mol Biomarkers, 13, 729-34.   DOI   ScienceOn
11 Fehri E, Ennaifer E, Ardhaoui M, et al (2014). Expression of Toll-like receptor 9 increases with progression of cervical neoplasia in Tunisian women-a comparative analysis of condyloma, cervical intraepithelial neoplasia and invasive carcinoma. Asian Pac J Cancer Prev, 15, 6145-50.   DOI
12 Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.   DOI   ScienceOn
13 Grimm M, Kim M, Rosenwald A, et al (2010). Toll-like receptor (TLR) 7 and TLR8 expression on CD133+cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur J Cancer, 46, 2849-57.   DOI   ScienceOn
14 Hao Y, Yuan JL, Abudula A, et al (2014). TLR9 expression in uterine cervical lesions of Uyghur women correlate with cervical cancer progression and selective silencing of human papillomavirus 16 E6 and E7 oncoproteins in vitro. Asian Pac J Cancer Prev, 15, 5867-72.   DOI
15 Hemmi H, Takeuchi O, Kawai T, et al (2000). A Toll-like receptor recognizes bacterial DNA. Nature, 408, 740-5.   DOI   ScienceOn
16 Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI   ScienceOn
17 Hold GL, Rabkin CS, Gammon MD, et al (2009). CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur J Cancer Prev, 18, 117-9.   DOI   ScienceOn
18 Lai ZZ, Ni Zhang, Pan XL, et al (2013). Toll-like receptor 9 (TLR9) gene polymorphisms associated with increased susceptibility of human papillomavirus-16 infection in patients with cervical cancer. J Int Med Res, 41, 1027-36.   DOI
19 Huang B, Zhao J, Li H, et al (2005). Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res, 65, 5009-14.   DOI   ScienceOn
20 Kutikhin AG (2011). Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol, 72, 1095-116.   DOI   ScienceOn
21 Latz E, Schoenemeyer A, Visintin A, et al (2004). TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol, 5, 190-8.   DOI   ScienceOn
22 Mantovani A, Allavena P, Sica A, et al (2008). Cancer-related inflammation. Nature, 454, 436-44.   DOI   ScienceOn
23 Li S, Dai Q, Yang Z (2012). Association between Toll-like receptor 9 polymorphisms and INF-${\gamma}$expression with colorectal carcinoma. Sichuan J Anatomy, 20, 12-5.
24 Mandal RK, George GP, Mittal RD (2012). Association of Tolllike receptor (TLR) 2, 3 and 9 genes polymorphism with prostate cancer risk in North Indian population. Mol Biol Rep, 39, 7263-9.   DOI
25 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
26 Miedema KG, Tissing WJ, Te PE, et al (2012). Polymorphisms in the TLR6 gene associated with the inverse association between childhood acute lymphoblastic leukemia and atopic disease. Leukemia, 26, 1203-10.   DOI
27 Noack J, Jordi M, Zauner L, et al (2012). TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism polymorphism. Cell Death Dis, 21, 323.
28 Mollaki V, Georgiadis T, Tassidou A, et al (2009). Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study. J Hum Genet, 54, 655-9.   DOI
29 Murad YM, Clay TM, Lyerly HK, et al (2007). CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther, 7, 1257-667.   DOI
30 Nieters A, Beckmann L, Deeg E, et al (2006). Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun, 7, 615-24.   DOI   ScienceOn
31 Oldenburg M, Kruger A, Ferstl R, et al (2012). TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistanceforming modification. Science, 337, 1111-5.   DOI   ScienceOn
32 Singh V, Srivastava N, Kapoor R, et al (2013). Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in a case-control study with bladder cancer susceptibility in a North Indian population. Arch Med Res, 44, 54-61.   DOI
33 Pandey S, Mittal B, Srivastava M, et al (2011). Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility. Mol Biol Rep, 38, 4715-21.   DOI
34 Resler AJ, Malone KE, Johnson LG, et al (2013). Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. BMC Cancer, 13, 219.   DOI
35 Roszak A, Lianeri M, Sowinska A, et al (2012). Involvement of Toll-like receptor 9 polymorphism in cervical cancer development. Mol Biol Rep, 39, 8425-30.   DOI
36 Zhang H, Ma H, Li L, et al (2013). Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis. PLoS One, 8, 69366.   DOI
37 Wang X, Xue L, Yang Y, et al (2013). TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. PLoS One, 8, 65731.   DOI
38 Xie J, Jiang S, Shi M, et al (2012). The association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility. BMC Cancer, 12, 57.   DOI   ScienceOn
39 Zeng H, Pan K, Zhang Y, et al (2011). The correlation between polymorphisms of Toll-like receptor 2 and Toll-like receptor 9and susceptibility to gastric cancer. Chin J Pre Med, 45, 588-92.
40 Zhang K, Zhou B, Wang Y, et al (2013). The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis. Eur J Cancer, 49, 946-54.   DOI
41 Zhang L, Qin H, Guan X, et al (2013). The TLR9 gene polymorphisms and the risk of cancer: evidence from a meta-analysis. PLoS One, 8, 71785.   DOI